Seven-year follow-up data show that transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement have ...
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...
7don MSN
Minimally invasive procedure for aortic valve disease has similar outcomes as surgery, study reports
People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...
A troubling rise in severe diverticulitis cases among Americans under 50 highlights a significant public health concern.
GlobalData on MSN
Edwards solidifies TAVR dominance in long-term trial readout
The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.
Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
GlobalData on MSN
Edwards boosts FY25 outlook after Q3 surpasses expectations
Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...
Medpage Today on MSN
First 7-Year Report of Low-Risk TAVR Reassures, With Finish Line Now in Sight
SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...
A Delaware judge correctly interpreted transcatheter aortic valve-replacement device patents that were asserted against Edwards Lifesciences Corp., the Federal Circuit ruled, clearing Edwards of ...
Abbott reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR) system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback